Phase I, Interventional, Single Arm, Open Label, Treatment Study to Evaluate the Safety and Tolerability of CD19 CARvac in Patients With Relapsed and/or Refractory B Cell Malignancies
Latest Information Update: 04 Nov 2021
Price :
$35 *
At a glance
- Drugs Anti-CD19 chimeric antigen receptor T cell therapy iCell Gene Therapeutics (Primary)
- Indications B-cell leukaemia; B-cell lymphoma; Haematological malignancies
- Focus Adverse reactions
- Sponsors iCell Gene Therapeutics
- 12 Nov 2019 New trial record